ArticleResearch and practice in thrombosis and haemostasis2020
Patient Experience of Living With Cancer-Associated Thrombosis in Canada (PELICANADA).
Article in Research and practice in thrombosis and haemostasis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Quality of life in oncological patients with venous thromboembolic disease.Research and practice in thrombosis and haemostasis · 2024Review
- Measurement of adherence and health-related quality of life during anticoagulation therapy in cancer-associated venous thromboembolism (VTE): a multicenter quantitative study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction.The oncologist · 2023Article
- Immune Checkpoint Inhibitors-Associated Thrombosis: Incidence, Risk Factors and Management.Current oncology (Toronto, Ont.) · 2023Review
- Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day.Journal of thrombosis and haemostasis : JTH · 2022Article
- Practical Considerations for the Management of Cancer-Associated Venous Thromboembolism: A Guide for the General Oncology Practitioner.Current oncology (Toronto, Ont.) · 2022Review
- Cancer-associated venous thromboembolism.Nature reviews. Disease primers · 2022Review
- Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study.Journal of thrombosis and thrombolysis · 2022Observational
- Article
- Cancer patients' experiences of the diagnosis and treatment of incidental pulmonary embolism (a qualitative study).PloS one · 2022Observational
- Article
- Emergency management of incidental pulmonary embolism (IPE).Emergency cancer care · 2022Review
- Clinical and sociodemographic factors associated with anticoagulant use for cancer associated venous thromboembolism.Journal of thrombosis and thrombolysis · 2021Article
- A mixed-methods study to evaluate a patient-designed tool to reduce harm from cancer-associated thrombosis: The EMPOWER study.Research and practice in thrombosis and haemostasis · 2021Article
- Review
- Patient Experience of Living With Cancer-Associated Thrombosis in Canada (PELICANADA).Research and practice in thrombosis and haemostasis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionPrevious research from the United Kingdom and Spain has identified several areas of unmet clinical and support need for cancer patients diagnosed with venous thromboembolism. It is not known whether such experiences are restricted to those countries health care systems and culture. We therefore evaluated patients' experience of cancer-associated thrombosis (CAT) within a Canadian setting.
methodsPurposive sampling of patients with CAT attending a regional thrombosis clinic in Vancouver was undertaken. Semistructured interviews were audio recorded, transcribed, and coded using NVivo software. A deductive approach was taken by applying the framework matrix from the original study to these data on a case-by-case basis.
resultsTwenty patients (10 male, 10 female) aged 39 to 74 (mean, 63) representing a breadth of different cancers participated. Commonalities between the UK and Canadian patients included the traumatic nature of experiencing CAT, the need for information, and adaptive behaviors through ritualization. Two new themes were identified: (1) Patients with incidental pulmonary emboli (iPE) were usually telephoned about their thrombus with little support and suboptimal communication; and (2) cost implications of accessing low-molecular-weight heparin varied according to insurance cover. Patients were sometimes converted to warfarin for financial reasons.
conclusionThe distress associated with CAT is a common experience across different populations but may be ameliorated by early access to specialist services, information, and support. The current process for managing iPE could be improved with better communication and a dedicated clinical pathway. Funding issues may influence choice of anticoagulant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.